Master of Science in Drug Regulatory Affairs and Policy
MSc(DRAP)
Both full-time and part-time
Full-time: 1 year
Part-time: 2 years
HK$300,000
Program Director:
Prof Karl TSIM, Chair Professor of Life Science
The Master of Science (MSc) Program in Drug Regulatory Affairs and Policy is a high-quality program offering training for drug regulatory affairs and policy professionals which is critical for Hong Kong and the Greater Bay Area. Establishment of the Hong Kong Centre for Medical Products Regulation (CMPR) is one of the highlights in the HKSAR Policy Address 2023. The office is set up to study the potential restructuring and strengthening of the current regulatory and approval regimes for medicine, medical devices and medical technology to accelerate the approval of applications and registration of pharmaceutical products for launching to the market. The program is unique for preparing students to become top managers and main practitioners of the guidance documents, laws, and regulations for pharmaceutical companies and/or government agencies. With this training and exposure, graduates from the program will be able to manage regulatory affairs positions at pharmaceutical, biotechnology, medical device, diagnostic and healthcare products companies, and government agencies in their careers.
On successful completion of the program, graduates will be able to:
- Understand the rationale behind, and basic management practices of, quality control and quality assurance of pharmaceutical product development.
- Develop a thorough understanding on the relevant laws/regulations and/or regulatory environment of drug registration in China or US market;
- Gain professional training in keeping up with the increasing scope and complexity of the governmental regulations;
- Enhance good personality and communication skills in pharmaceutical regulations and policy;
- Serve as the top management and become main practitioners of the laws and regulations for pharmaceutical companies and/or government agencies; advising them on the regulatory aspects and climate that would affect their proposed activities; and
- Ensure that the pharmaceutical companies comply with the regulations of NMPA or FDA drug registration and laws pertaining to their business, and work with central, provincial and local regulatory agencies and personnel on specific issues affecting their business.
Last update: 22 Mar 2024
-
Minimum Credit Requirement
30 credits
-
Required Courses
12 credits
-
Elective Courses
18 credits
Students are required to take at least three DRAP courses from the following list:
To qualify for admission, applicants must meet all of the following requirements. Admission is selective and meeting these minimum requirements does not guarantee admission.
-
Applicants seeking admission to a master's degree program should have obtained a bachelor’s degree from a recognized institution, or an approved equivalent qualification.
Applicants have to fulfill English Language requirements with one of the following proficiency attainments:
-
TOEFL-iBT: 80 *
-
TOEFL-pBT: 550
-
TOEFL-Revised paper-delivered test: 60 (total scores for Reading, Listening and Writing sections)
-
IELTS (Academic Module): Overall score: 6.5 and All sub-score: 5.5 *
* Refers to scores in one single attempt only. Test at home option is not accepted.
Applicants are not required to present TOEFL or IELTS score if
-
their first language is English, or
-
they obtained the bachelor's degree (or equivalent) from an institution where the medium of instruction was English.
-
A bachelor's degree or above in life sciences, business management, engineering, health science, law, computer sciences, mathematics, and other relevant disciplines.
-
Relevant work experience in areas such as pharmaceuticals, medical devices, or health-related industry will be highly favorable.
Last update: 22 Mar 2024